For AI assistants & researchers — machine-readable summary of this page
What this page is: Delvantic's full research page for Viatris Inc. (VTRS) — AI-driven forensic equity research: mechanical valuation models (DCF, EPV, anchored-PE, scenario) plus three independent AI lenses (Quality / Value / Sentiment). Everything below is rendered server-side; you are not missing content that requires JavaScript. All scores are predictions and research opinions, not financial advice.
Page map (sections in order; each card carries a stable
reference-name attribute you can cite):
profile-header/price-overview— company profile, live quote, market capextended-analysis— the core: three AI lens reads with findings, scores, and the analyst memofuture-predictions— our forward price-band predictionsmarket-narrative/ai-findings/gpt-critique— narrative context, cross-model findings, and an adversarial critique of our own analysis (near the end of the document)- Members-only sections (render as login gates for anonymous readers):
price-history,income-trend,key-metrics,financials(statement tables),insider-trading. The analysis above is public; the raw data tables require a free account.
More for machine readers: site briefing at
/llms.txt ·
any ticker resolves at delvantic.com/stock/TICKER ·
raw inputs are public-company filings and market data (via licensed data feeds);
every model, score, lens read, and prediction on this page is Delvantic's own analysis.
Viatris Inc.
VTRS NASDAQ
Healthcare · Drug Manufacturers - Specialty & Generic
Canonsburg, PA 15317, United States
viatris.com
Price
$16.63
Market Cap
$19.1B
Employees
30,000
Beta
0.89
Avg Volume
9,730,437
Last Dividend
$0.48
CEO
Mr. Scott Andrew Smith Ph.D.
Viatris Inc. is a global healthcare company focused on expanding access to a broad range of medicines across multiple therapeutic areas. Its portfolio includes established prescription brands, generic and complex generic medicines, biosimilars, and over-the-counter consumer products that support treatment and disease management worldwide. Viatris serves patients and healthcare systems in developed and emerging markets through operations organized across Developed Markets, Greater China, JANZ, and Emerging Markets. The company also emphasizes reliable manufacturing, distribution, and supply continuity for essential therapies, helping connect more people to trusted medicines regardless of geography or circumstance. Headquartered in Canonsburg, Pennsylvania, Viatris operates as a diversified pharmaceutical business with a broad international footprint and a focus on scalable healthcare access.
Runs with full report
Price Overview
Price at report time
$16.63
as of Sep 1, 4:42pm (36d ago)
Change · Sep 1
+0.12 (+0.73%)
Day Range
$16.51 – $16.91
52-Week Range
$9.43 – $18.39
50-Day MA
$16.70
200-Day MA
$14.63
Volume
6,519,961.00
Right now · live
Log in to get the live feed
Members see the real-time price and the move since this report (over 36d).
Share Structure
Outstanding
1,155,236,182.00
Float
1,141,791,206.00
Free Float
98.8%
High free float
— 98.8% of shares trade freely, ~1.2% held by insiders/institutions
Very liquid — most shares trade freely. Low insider ownership can mean less management alignment, but makes large position sizing straightforward.
Price History (1 Year)
Revenue & Net Income Trend
The directional story — useful even when net income is negative.
Revenue
The top line — total sales before any costs or taxes are subtracted. A measure of how much business the company is doing.
Net Income
The bottom line — profit left after subtracting all expenses, interest, and taxes from revenue. Reflects accounting profitability, but includes non-cash items like depreciation, so it isn't the same as cash earned.
Operating Cash Flow
The real cash generated by the day-to-day business — selling products, paying suppliers, collecting from customers. Calculated from net income by adding back non-cash items and adjusting for timing (unpaid bills, unsold inventory). When OCF consistently lags net income, the reported profit may not be converting to real money.
| Period | Revenue | Net Income | Net Margin | YoY/QoQ |
|---|
Key Metrics
TD Twelve Data statement
HEX SEC filing
P/E · trailing (TTM) (Price per dollar of earnings over the past year — not a run-rate or forward P/E)
HEXStock Price / EPS (Diluted)
-5.54
Stock Price: $16.63
EPS (Diluted): -3.00
EPS (Diluted): -3.00
P/B Ratio (Price vs net asset value)
HEXStock Price / Book Value Per Share
1.32
Stock Price: $16.63
Total Equity: $14.71B
Shares: 1,171,633,333
Total Equity: $14.71B
Shares: 1,171,633,333
EV/EBITDA (Total value vs operating profit)
HEXEnterprise Value / EBITDA
240.92
Market Cap: $19.10B
Total Debt: $14.41B
Cash: $1.32B
EBITDA: $135.20M
Total Debt: $14.41B
Cash: $1.32B
EBITDA: $135.20M
Enterprise Value (Takeover price (cap + debt - cash))
HEXMarket Cap + Total Debt - Cash
$32.6B
Market Cap: $19.10B
Total Debt: $14.41B
Cash: $1.32B
Total Debt: $14.41B
Cash: $1.32B
P/S Ratio (Price per dollar of revenue)
HEXStock Price / Revenue Per Share
1.36
Stock Price: $16.63
Revenue: $14.30B
Shares: 1,171,633,333
Revenue: $14.30B
Shares: 1,171,633,333
EV/Sales (Total value vs revenue — works when P/E can't)
CALC2.28
Gross Margin (Revenue left after direct costs)
HEXGross Profit / Revenue
35.1%
Gross Profit: $5.01B
Revenue: $14.30B
Revenue: $14.30B
Operating Margin (Revenue left after all operations)
HEXOperating Income / Revenue
-18.6%
Operating Income: -$2.66B
Revenue: $14.30B
Revenue: $14.30B
Net Margin (Revenue left as actual profit)
HEXNet Income / Revenue
-24.6%
Net Income: -$3.51B
Revenue: $14.30B
Revenue: $14.30B
ROE (Profit from shareholder equity)
HEXNet Income / Total Equity
-23.9%
Net Income: -$3.51B
Total Equity: $14.71B
Total Equity: $14.71B
ROIC (Profit from all invested capital)
HEXNOPAT / Invested Capital
-9.2%
Operating Income: -$2.66B
Tax Rate: 4.1%
Equity: $14.71B
Total Debt: $14.41B
Cash: $1.32B
Tax Rate: 4.1%
Equity: $14.71B
Total Debt: $14.41B
Cash: $1.32B
Current Ratio (Can it pay short-term bills)
HEXCurrent Assets / Current Liabilities
1.38
Current Assets: $9.79B
Current Liabilities: $7.09B
Current Liabilities: $7.09B
Debt/Equity (Leverage — debt vs equity)
HEXTotal Debt / Total Equity
0.98
Short-Term Debt: $1.93B
Long-Term Debt: $12.48B
Total Debt: $14.41B
Total Equity: $14.71B
Long-Term Debt: $12.48B
Total Debt: $14.41B
Total Equity: $14.71B
Rev/Share (Top-line per share)
HEXRevenue / Shares Outstanding
$12.21
Revenue: $14.30B
Shares: 1,171,633,333
Shares: 1,171,633,333
Book Value/Share (Net assets per share)
HEX(Total Assets - Total Liabilities) / Shares
$12.56
Total Equity: $14.71B
Shares: 1,171,633,333
Shares: 1,171,633,333
FCF/Share (Real cash generated per share)
HEX(Operating Cash Flow + CapEx) / Shares
$1.65
Operating CF: $2.32B
CapEx: -$378.80M
Shares: 1,171,633,333
CapEx: -$378.80M
Shares: 1,171,633,333
CapEx is negative (outflow) — added to OCF to get FCF
Div Yield (Annual income from holding)
TDLast Annual Dividend / Stock Price
2.9%
Last Dividend: $0.48
Stock Price: $16.63
Stock Price: $16.63
Payout Ratio (Earnings paid out as dividends)
HEXDividends Paid / Net Income
—
Dividends Paid: N/A
Net Income: -$3.51B
Net Income: -$3.51B
Dividends paid not available in cash flow statement
Industry Benchmarks
Compares VTRS against LLM-researched typical ranges for its
industry. One research call per industry, cached indefinitely — every stock in the same industry
reuses the same baseline.
Income Statement (Annual)
Last updated: Sep 1, 2026 4:45pm (36d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | $17.9B | $16.3B | $15.4B | $14.7B | $14.3B |
| Cost of Revenue | $12.3B | $9.8B | $9.0B | $9.1B | $9.3B |
| Gross Profit | $5.6B | $6.5B | $6.4B | $5.6B | $5.0B |
| Operating Expenses | $5.6B | $4.9B | $5.7B | $5.6B | $7.7B |
| Operating Income | -$34.0M | $1.6B | $766.2M | $10.1M | -$2.7B |
| Net Income | -$1.3B | $2.1B | $54.7M | -$634.2M | -$3.5B |
| EBITDA | $4.5B | $4.6B | $3.5B | $2.9B | $135.2M |
| EPS | $-1.05 | $1.71 | $0.05 | $-0.53 | $-3.00 |
| EPS (Diluted) | $-1.05 | $1.71 | $0.05 | $-0.53 | $-3.00 |
Balance Sheet (Annual)
Last updated: Sep 1, 2026 4:42pm (36d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | $701.2M | $1.3B | $991.9M | $734.8M | $1.3B |
| Total Current Assets | $10.9B | $10.6B | $13.0B | $9.5B | $9.8B |
| Total Assets | $54.8B | $50.0B | $47.7B | $41.5B | $37.2B |
| Current Liabilities | $9.9B | $6.7B | $7.8B | $5.8B | $7.1B |
| Long-Term Debt | $19.7B | $18.0B | $16.2B | $14.0B | $12.5B |
| Total Liabilities | $34.4B | $28.9B | $27.2B | $22.9B | $22.5B |
| Total Equity | $20.5B | $21.1B | $20.5B | $18.6B | $14.7B |
| Retained Earnings | $3.7B | $5.2B | $4.6B | $3.4B | -$388.3M |
Cash Flow (Annual)
Last updated: Sep 1, 2026 4:50pm (36d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | $3.0B | $3.0B | $2.8B | $2.3B | $2.3B |
| Capital Expenditure | -$457.2M | -$406.0M | -$377.0M | -$326.0M | -$378.8M |
| Free Cash Flow | $2.6B | $2.5B | $2.4B | $2.0B | $1.9B |
| Acquisitions (net) | $277.0M | $0 | -$667.7M | -$350.0M | $0 |
| Net Debt Issued / (Repaid) | -$2.5B | -$1.8B | -$1.2B | -$3.7B | $-100,000 |
| Dividends Paid | — | — | — | — | — |
| Stock Buybacks | $0 | $0 | -$250.0M | -$250.0M | -$500.5M |
| Net Change in Cash | -$143.8M | $556.3M | -$268.9M | -$257.5M | $611.9M |
Growth Trends (YoY %)
Last updated: Sep 1, 2026 4:45pm (36d ago)| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue Growth | -9.1% | -5.1% | -4.5% | -3.0% |
| Gross Profit Growth | +16.5% | -0.9% | -12.7% | -10.8% |
| Operating Income Growth | +4,849.7% | -52.6% | -98.7% | -26,467.3% |
| Net Income Growth | +263.8% | -97.4% | -1,259.4% | -454.2% |
| EBITDA Growth | +3.8% | -24.5% | -17.2% | -95.3% |
Dividend History (Last 20)
Last updated: Sep 1, 2026 4:42pm (36d ago)| Date | Dividend | Declaration | Record | Payment |
|---|---|---|---|---|
| 2026-08-21 | $0.12 | — | — | — |
| 2026-05-22 | $0.12 | — | — | — |
| 2026-03-09 | $0.12 | — | — | — |
| 2025-11-24 | $0.12 | — | — | — |
| 2025-08-22 | $0.12 | — | — | — |
| 2025-05-23 | $0.12 | — | — | — |
| 2025-03-10 | $0.12 | — | — | — |
| 2024-11-22 | $0.12 | — | — | — |
| 2024-08-23 | $0.12 | — | — | — |
| 2024-05-23 | $0.12 | — | — | — |
| 2024-03-08 | $0.12 | — | — | — |
| 2023-11-22 | $0.12 | — | — | — |
| 2023-08-23 | $0.12 | — | — | — |
| 2023-05-23 | $0.12 | — | — | — |
| 2023-03-08 | $0.12 | — | — | — |
| 2022-11-22 | $0.12 | — | — | — |
| 2022-08-23 | $0.12 | — | — | — |
| 2022-05-23 | $0.12 | — | — | — |
| 2022-02-23 | $0.12 | — | — | — |
| 2021-11-22 | $0.11 | — | — | — |
Deep Analysis
0Company Classification
1Industry Landscape
2Company Momentum
3Forward Projection
4aDCF Valuation
4bEarnings Power Value
4cAnchored PE
4dReverse DCF
4eRevenue-Based DCF
4fAnchored P/S
4gScenario Analysis
4hDividend Discount Model
4iBook Value Analysis
4jInsider Activity
4fCash Flow Quality
4gDebt Maturity Risk
4hMacro Environment
4iSector Intelligence
4jRevenue Confidence
4kSensitivity Analysis
4lSector Demand Cycle
5AI Investigation
5bThesis Evaluation
6Valuation Synthesis
computed
not applicable
not yet run 0 computed · 7 not applicable · 17 not yet run
Risk : Reward — upside vs downside from this company's own quarters
Not computed yet
Why there is no ratio: Risk:reward has not been computed for this name yet — its report predates the mechanical valuation chain. It is added, at $0, the next time a report or the nightly touches this ticker.
Narrative Economics
The story the market is telling about this stock — the intangible X-factor
(founder mythology, cult dynamics, TAM-of-imagination) that moves price beyond
what cash flows alone explain. After Shiller, Narrative Economics.
No narrative profile yet for VTRS — it's generated by the pipeline (
market-narrative step).
Claude Reading
No AI findings yet for VTRS — they're generated by the
pipeline (
ai-findings step) when a report is run on this ticker.
GPT Reading
Skipped in the Qwen lane lane by design —
the GPT seat runs only in the full report.
Grok Reading
Skipped in the Qwen lane lane by design —
the Grok seat runs only in the full report.
Advanced Analysis Forensic deep-dive · separate lenses
No community reviews yet for VTRS.
Be the first — hit How to Contribute, have any AI review this page, and paste its take back here.
My Notes
personal — only you see this
Sign in to save personal notes and rate your interest in this stock.
v1.1.760 · f4b58a28 · 2026-10-07 20:07:48